(Q35456042)

English

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

0 references

0 references

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

author name string

Liu C

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Blumhardt LD

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

0 references

publication date

1 April 2000

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Journal of Neurology, Neurosurgery and Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

68

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

450-457

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Imaging axonal damage of normal-appearing white matter in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Axonal transection in the lesions of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Clinical outcome measures and rating scales in multiple sclerosis trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Axonal damage in acute multiple sclerosis lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Clinical outcomes assessment in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

More immunotherapy for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Design strategies in multiple sclerosis clinical trials. The Cyclosporine Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

12 July 2018

The psychometric properties of clinical rating scales used in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

26 September 2018

Interferon beta therapy for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

26 September 2018

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1736854

26 September 2018

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10727480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/10727480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10727480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10727480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Some aspects of the natural history of disseminated sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10727480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognosis and treatment of multiple sclerosis-quantitative nosometric study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10727480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/10727480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://pubmed.ncbi.nlm.nih.gov/10727480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of the placebo-treated groups in clinical trials of progressive MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/10727480

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/JNNP.68.4.450

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35456042&oldid=1629630299"